Novartis Ag (NVS) Receivables Refunds (2017 - 2025)
Novartis Ag (NVS) has disclosed Receivables Refunds for 9 consecutive years, with $205.0 million as the latest value for Q4 2025.
- Quarterly Receivables Refunds rose 54.14% to $205.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $205.0 million through Dec 2025, up 54.14% year-over-year, with the annual reading at $205.0 million for FY2025, 54.14% up from the prior year.
- Receivables Refunds hit $205.0 million in Q4 2025 for Novartis Ag, up from $133.0 million in the prior quarter.
- In the past five years, Receivables Refunds ranged from a high of $426.0 million in Q4 2023 to a low of $133.0 million in Q4 2024.
- Historically, Receivables Refunds has averaged $262.0 million across 5 years, with a median of $268.0 million in 2022.
- Biggest five-year swings in Receivables Refunds: soared 58.96% in 2023 and later tumbled 68.78% in 2024.
- Year by year, Receivables Refunds stood at $278.0 million in 2021, then decreased by 3.6% to $268.0 million in 2022, then skyrocketed by 58.96% to $426.0 million in 2023, then crashed by 68.78% to $133.0 million in 2024, then soared by 54.14% to $205.0 million in 2025.
- Business Quant data shows Receivables Refunds for NVS at $205.0 million in Q4 2025, $133.0 million in Q4 2024, and $426.0 million in Q4 2023.